Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.
- Trial name
- PSORITUS (NCT02362789)
- Testing
- Secukinumab
- Where
- 19 sites in Germany
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06973291
- Testing
- Zasocitinib, Deucravacitinib
- Where
- 113 sites in United States, Bulgaria and 6 more
- Volunteers
- 606 people
- Sponsor
- Takeda
Psoriasis
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
This study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and other…
- Trial name
- NCT01837420
- Testing
- VB-201 80mg, VB-201 160mg
- Where
- 4 sites in Germany, Israel and 2 more
- Volunteers
- 194 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Psoriasis
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) =…
- Trial name
- GUIDE (NCT03818035)
- Testing
- Guselkumab
- Where
- 90 sites in France, Germany
- Volunteers
- 880 people
- Sponsor
- Janssen-Cilag International NV
Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07326813
- Testing
- D-2570 Tablet, BMS-986165 Tablet
- Where
- China
- Volunteers
- 477 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events.
- Trial name
- NCT01320293
- Testing
- Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of North Carolina, Chapel Hill
Psoriasis
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic…
- Trial name
- NCT03478787
- Testing
- risankizumab, secukinumab
- Where
- 61 sites in United States, Canada and 7 more
- Volunteers
- 327 people
- Sponsor
- AbbVie
Psoriasis
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis.
- Trial name
- NCT00954915
- Testing
- teplizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Scalp Psoriasis
Subject Preference for Scalp Psoriasis Treatment
The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress.
- Trial name
- NCT00438399
- Testing
- C. propionate - Corticosteroid 1, C. propionate- Corticosteroid 2, C. propionate -Corticosteroid 3
- Where
- Italy
- Volunteers
- 219 people
- Sponsor
- Galderma R&D
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Moderate to Severe Psoriasis
Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing
JS005-002 is a randomized, double-blinded, placebo-controlled phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of multiple doses of JS005 (recombinant humanized anti-IL-17A…
- Trial name
- NCT05344248
- Testing
- JS005 (recombinant humanized monoclonal antibody against IL-17A)
- Where
- 22 sites in China
- Volunteers
- 183 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Psoriasis
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral…
- Trial name
- NCT02576678
- Testing
- Apremilast
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 42 people
- Sponsor
- Amgen
Psoriasis Vulgaris
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
This study investigates if an adjusted brodalumab dosage regimen will give improved efficacy in psoriasis in patients with a body weight of over 120 kg.
- Trial name
- ADJUST (NCT04306315)
- Testing
- Brodalumab
- Where
- 81 sites in Belgium, Czechia and 9 more
- Volunteers
- 385 people
- Sponsor
- LEO Pharma
Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03701763
- Testing
- Apremilast (CC-10004)
- Where
- 99 sites in United States, Belgium and 8 more
- Volunteers
- 245 people
- Sponsor
- Amgen
Psoriasis
A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
The purpose of this study is to determine if infliximab (anti-TNF) is effective in the treatment of plaque psoriasis.
- Trial name
- NCT00106834
- Testing
- Infliximab
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Psoriasis (PsO), Enthesitis
A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)
It is an observational, single-center, prospective, exploratory, open-label study to assess the efficacy and safety of IL-17 inhibitors on subclinical enthesitis in patients with moderate to severe psoriasis with subclinical…
- Conditions
- Psoriasis (PsO), Enthesitis, Psoriasis Arthritis, Secukinumab
- Trial name
- NCT06987292
- Testing
- IL-17i
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Psoriasis
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the…
- Trial name
- NCT01001208
- Testing
- Methotrexate, Etanercept
- Volunteers
- 478 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.
- Trial name
- NCT00245765
- Testing
- Certolizumab Pegol
- Where
- 15 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- UCB Pharma